Xtl Biopharma Story

<div class='circular--portrait' style='background:#008000;color: #FFE4E1;font-size:4em;'>XB</div>
XTLB -- USA Stock  

USD 3.14  0.06  1.88%

It appears Xtl Biopharma will continue to recover much faster as its share price surged up 29.76% today. The company current daily volatility is 7.4 percent, with a beta of 0.66 and an alpha of 0.31 over DOW. While many traders are getting carried away by overanalyzing current volatility, it is reasonable to go over Xtl Biopharma Ads. We will evaluate why recent Xtl Biopharma price moves suggest a bounce in April.
Published over a month ago
View all stories for Xtl Biopharma | View All Stories
Is Xtl Biopharma (NASDAQ:XTLB) a good short term trade as volatility builds up?
This firm conducts business under Healthcare sector and is part of Biotechnology industry.
We provide recommendation to complement the prevalent expert consensus on Xtl Biopharma Ads. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
Investing in Xtl Biopharma, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Xtl Biopharma along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Xtl Biopharma's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Xtl Biopharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Xtl Biopharma. Your research has to be compared to or analyzed against Xtl Biopharma's peers to derive any actionable benefits. When done correctly, Xtl Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Xtl Biopharma Ads.

How important is Xtl Biopharma's Liquidity

Xtl Biopharma financial leverage refers to using borrowed capital as a funding source to finance Xtl Biopharma Ads ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Xtl Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Xtl Biopharma's total debt and its cash.

How Xtl Biopharma utilizes its cash?

To perform a cash flow analysis of Xtl Biopharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Xtl Biopharma is receiving and how much cash it distributes out in a given period. The Xtl Biopharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Xtl Biopharma Correlation with Peers

Investors in Xtl Biopharma can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Xtl Biopharma Ads. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Xtl Biopharma and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Xtl Biopharma is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Xtl Biopharma for more details

Purchase by Edelman Joseph of 376000 shares of Xtl Biopharma

Legal trades by Xtl Biopharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Xtl Biopharma insider trading alert for perchase of ordinary shares by Edelman Joseph, the corporate stakeholder, on 9th of April 2021. This event was filed by Xtl Biopharmaceuticals Lt with SEC on 2008-02-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Xtl Biopharma Ads

Xtl Biopharma is dangerous given 1 month investment horizon. Xtl Biopharma Ads shows Sharpe Ratio of 0.15, which attests that the company had 0.15% of return per unit of risk over the last month. Our standpoint towards determining the risk of a stock is to use both market data as well as company specific technical data. We were able to break down and interpolate twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.08% are justified by taking the suggested risk. Use Xtl Biopharma Ads Market Risk Adjusted Performance of 0.5276, downside deviation of 4.32, and Mean Deviation of 4.16 to evaluate company specific risk that cannot be diversified away.
NVO
REGN
CSLLY
WXIBF
BGNE
NVO
-0.08-0.210.60.7
NVO
REGN
-0.080.00.080.19
REGN
CSLLY
-0.210.0-0.51-0.53
CSLLY
WXIBF
0.60.08-0.510.85
WXIBF
BGNE
0.70.19-0.530.85
BGNE
NVO
REGN
CSLLY
WXIBF
BGNE
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Our take on today Xtl Biopharma rise

Current skewness is at 0.85. Xtl Biopharma Ads exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Xtl Biopharma Ads individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Xtl Biopharma future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Xtl Biopharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Xtl Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Xtl Biopharma

Whereas some other firms under the biotechnology industry are still a bit expensive, Xtl Biopharma may offer a potential longer-term growth to investors. Taking everything into account, as of the 5th of March 2021, our analysis shows that Xtl Biopharma follows the market closely. The company is overvalued and projects below average odds of distress for the next 2 years. Our ongoing 30 days recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Xtl Biopharma Ads. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com